MustGrow Biologics Corp: Strategic Shift and Financial Outlook

MustGrow Biologics Corp, a Canadian agriculture company, is progressing from a development platform to a focused biologicals enterprise, led by its product TerraSante. Previously, the company relied on third-party distribution but is now centering on its proprietary solutions. Initial revenue increases were seen in FY 2025, fueled by collaboration income, following a dip after FY 2023.

The Q1 2026 report confirms a strategic transition toward organic revenue, mainly from TerraSante, achieving a 23.6% gross margin. MustGrow forecasts significant revenue growth by FY 2028, driven by expanding TerraSante adoption, with a projected EBITDA turnaround as the product scales.

Financial stability remains a priority, with recent financing bolstering liquidity and supporting TerraSante production. The company is rated "BUY" with a target price of CAD 2.70, reflecting the potential seen in its focused business model and strategic partnerships, such as with Bayer.